Murmur, HeartNCT04400513
Development of an Algorithm to Differentiate Heart Murmurs Using Electronic Stethoscopes
An observational study of Murmur, Heart and Aortic Valve Stenosis, run by Eko Devices, Inc. at 1 site in United States.
Trial summary
The Eko CORE and DUO stethoscopes are FDA-approved electronic devices that have the capacity to record heart sounds. The study seeks to expand murmur detection to include VHD classification through the development of novel ML algorithms that are able to distinguish between systolic vs. diastolic vs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Murmur, Heart, Aortic Valve Stenosis, Tricuspid Regurgitation
- What is being tested?
- Use of Eko CORE and Eko DUO electronic stethoscopes
- Type of treatment
- Medical device
- How many people
- 1,145 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Jun 2020to 31 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Potential research subjects will be screened for eligibility from cardiology clinics, echocardiogram clinics, and inpatient areas. Alternatively, potential subjects will be identified in the echocardiography clinic the day of their echocardiogram appointment and approached for participation once eligibility is confirmed.
Who may be able to join
- Adults aged 18 years and older
- Patient or patient's legal healthcare proxy consents to participation
- Have an audible heart murmur in at least one auscultation position, as heard by a clinician
- Undergoing or have undergone a complete (i.e., not limited) echocardiogram
- Willing to have heart recordings done with two different electronic stethoscopes
Who cannot join
- Patient or proxy is unwilling or unable to give written informed consent
- Unable to complete a full clinical echocardiogram
- No audible heart murmur in at least one auscultation position, as heard by a clinician
- Experiencing a known or suspected acute cardiac event
- Mechanical ventricular support (such as ECMO, LVAD, RVAD, BiVAD, Impella, intra-aortic balloon pumps, TAH, VentrAssist, DuraHeart, HVAD, EVAHEART LVAS, HeartMate, Jarvik 2000)
- Unwilling or unable to follow or complete study procedures
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Development of an Algorithm to Differentiate Heart Murmurs by Timing, Disease Type, and Severity in Adult Patients Using Electronic Stethoscopes
The Eko CORE and DUO stethoscopes are FDA-approved electronic devices that have the capacity to record heart sounds. The study seeks to expand murmur detection to include VHD classification through the development of novel ML algorithms that are able to distinguish between systolic vs. diastolic vs. continuous murmurs, as well as classify VHD type and severity, using 4-point auscultation with Eko CORE and DUO electronic stethoscopes to record heart sounds.
Read the detailed description
Valvular heart disease (VHD), a subclass of structural heart disease (SHD), is a major cause of mortality and reduced quality of life for tens of millions of patients worldwide. Detecting VHD early allows the disease to be carefully monitored so that surgery can be considered as soon as the stenosis progresses to severe. Unfortunately, it is difficult for many clinicians to accurately identify VHD in its early stages and assess its severity through physical examination alone. This difficulty stems from both the subtlety of symptoms associated with VHD, and from clinicians' inability to reliably detect the heart murmurs indicative of VHD using a traditional stethoscope, particularly in the noisy and rushed environments characteristic of many healthcare settings.
AS, mitral regurgitation (MR), and tricuspid regurgitation (TR) all result in reliably reproducible auscultatory findings. Yet despite this, auscultation as a diagnostic procedure is notoriously poor: its accuracy to detect AS, MR, and TR ranges only from 5-40%. In addition, diastolic and continuous murmurs, which are rarer than the systolic murmurs caused by AS, MR and TR, and almost always pathologic, are usually very difficult to detect by frontline clinicians. Diastolic murmurs are typically caused by VHD such as aortic regurgitation (AR), pulmonic regurgitation (PR), mitral stenosis (MS), or tricuspid stenosis (TS), and continuous murmurs are typically caused by non-valvular forms of SHD, such as congenital aortopulmonary window, shunts, and patent ductus arteriosus (PDA). Missing one of these murmurs could lead to significantly delayed diagnosis and care.
Because of how difficult it is for clinicians to reliably screen for SHD through history taking and physical examination, the diagnosis of SHD relies heavily on echocardiography (echos), which is accepted as the gold standard for diagnosis of SHD severity by the cardiology community. The consequence of this is several-fold. First, many patients receive echos that would not be necessary if better screening and assessment tools existed. Second, echocardiography makes up a disproportionately large segment of healthcare expenditure. Third, patients are burdened with the responsibility of getting repeated echos due to the lack of better screening tools. The emotional, physical, and financial burden that accompanies such excessive testing, especially for patients living in underserved communities, cannot be overstated.
Overall, there is a growing need for better preliminary screening tools that would identify these conditions, even when asymptomatic, early on and more consistently, to a degree of accuracy comparable to gold standard echocardiography. Such a tool would improve clinicians' confidence in their assessment during physical exams, which would enable them to help their patients make informed care decisions, offer disease-altering therapies, and at the same time reduce the reliance on, and frequency of, unnecessary and expensive auxiliary workups. Lastly, by facilitating early detection of VHD, morbidity and mortality rates would be expected to decrease due to earlier intervention.
The FDA-approved Eko CORE and Eko DUO electronic stethoscopes offer clinicians a familiar and inexpensive tool that is widely accepted by patients, while at the same time offer sensors and technology that can improve screening and detection of medical conditions such as valve disease, as compared to auscultation with the traditional stethoscope. Both CORE and DUO feature sound amplification during auscultation, which improves the ability for the clinician to detect nuanced changes in heart sounds and patterns. The CORE allows recording of the audio to produce a phonocardiogram (PCG), while the DUO is able to record audio to produce a PCG as well as simultaneous recording of a single-lead electrocardiogram (ECG). Both devices use Bluetooth to wirelessly transmit PCG and ECG data to the Eko mobile application, which allows clinicians to visualize PCG and ECG as they auscultate, as well as to playback heart sound recordings, annotate notes on recorded audio, and save and share recordings. These features uniquely situate Eko electronic stethoscopes to be highly effective as preliminary screening tools in clinical practice.
Eko Devices has developed and received 510(k) FDA approval for a machine-learning (ML) algorithm that can detect the presence or absence of heart murmur in adult patients with VHD, using either the Eko CORE or DUO electronic stethoscopes to record heart sounds. This algorithm was built using a deep neural network model trained on 5,878 PCG recordings collected on Eko CORE and Eko DUO from over 5,318 unique patients to classify heart sound recordings as containing a heart murmur or containing no audible murmur, and to discriminate good quality heart sound recordings from poor quality heart sound recordings. The trained model has been independently validated in a multi-site clinical study that enrolled 681 VHD patients with matched gold-standard echocardiograms. FDA approval was received in January 2020.
The present study seeks to expand murmur detection to include VHD classification through the development of novel ML algorithms that are able to distinguish between systolic vs. diastolic vs. continuous murmurs, as well as classify VHD type and severity, using 4-point auscultation with Eko CORE and DUO electronic stethoscopes to record heart sounds. These new algorithms will integrate the time-synchronized ECG streams from DUO to improve distinction between S1 and S2 heart sounds and improve performance of identifying systolic vs. diastolic time intervals. When combined with the FDA-approved algorithm for signal quality and murmur detection, these new algorithms will enable clinicians to have a complete VHD decision support system, as based on ACC/AHA Patient Management Guidelines, when using Eko stethoscopes in their clinical practice.20 This will arm clinicians with information to help them detect SHD early, make clinical care decisions with confidence and consistency, and improve overall patient outcomes while decreasing cost and increasing efficiency.
- Conditions
- Murmur, Heart, Aortic Valve Stenosis, Tricuspid Regurgitation, Mitral Regurgitation, Innocent Murmurs, Heart Murmurs
- Being tested
- Use of Eko CORE and Eko DUO electronic stethoscopes
- Keywords
- artificial intelligence, machine learning
- Medical subject headings
- Heart Murmurs, Aortic Valve Stenosis, Tricuspid Valve Insufficiency, Mitral Valve Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Use of Eko CORE and Eko DUO electronic stethoscopesDevice
Auscultation of heart sounds using electronic stethoscopes
| Study group | Role | What they receive |
|---|---|---|
| Aortic Stenosis | Subjects with echo-confirmed AS graded moderate-to-severe or worse Receives: Device: Use of Eko CORE and Eko DUO electronic stethoscopes | |
| Mitral Regurgitation | Subjects with echo-confirmed MR graded moderate-to-severe or worse Receives: Device: Use of Eko CORE and Eko DUO electronic stethoscopes | |
| Tricuspid Regurgitation | Subjects with echo-confirmed TR graded moderate-to-severe or worse Receives: Device: Use of Eko CORE and Eko DUO electronic stethoscopes | |
| Innocent Murmur | Subjects with echo-confirmed trace/trivial valve disease severity Receives: Device: Use of Eko CORE and Eko DUO electronic stethoscopes | |
| Diastolic Murmur | Subjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS) Receives: Device: Use of Eko CORE and Eko DUO electronic stethoscopes | |
| Continuous Murmur | Subjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA) Receives: Device: Use of Eko CORE and Eko DUO electronic stethoscopes |
What is being measured
The primary outcome is the main question the study is designed to answer.
Murmur Timing
Develop a model that can classify murmurs based on the timing of the murmur in the cardiac cycle, allowing the algorithm to distinguish between systolic, diastolic, and continuous murmurs using time-synchronized ECG and PCG data.
Measured: Within two minutes of device use
Secondary outcomes (2)
Systolic Murmur Type Classification
Develop a model that can classify systolic murmurs into disease categories including aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR), other (O), and innocent murmurs (I).
Measured: Within two minutes of device use
Systolic Murmur Severity Classification
Develop a model that can grade the severity of AS, MR, and TR following the American Society of Echocardiography (ASE) guidelines as mild, moderate, or severe.
Measured: Within two minutes of device use
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2020
- Study start25 Jun 2020
- Primary completion30 Jun 2021
- Study completion31 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Murmur, HeartStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 1,145 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eko Devices, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04400513
- Sponsor's protocol ID
- 2020.3
- Status last verified
- Feb 2023
- First submitted
- 18 May 2020
- Last updated
- 15 Feb 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of an Algorithm to Differentiate Heart Murmurs by Timing, Disease Type, and Severity in Adult Patients Using Electronic Stethoscopes
- ClinicalTrials.gov ID
- NCT04400513
- Acronym / sponsor ID
- 2020.3
- Conditions
- Murmur, Heart, Aortic Valve Stenosis, Tricuspid Regurgitation, Mitral Regurgitation, Innocent Murmurs, Heart Murmurs
- Keywords
- artificial intelligence, machine learning
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,145 participants (actual)
- Lead sponsor
- Eko Devices, Inc.Industry (pharma, biotech, devices)
- Study start
- 25 Jun 2020 (actual)
- Primary completion
- 30 Jun 2021 (actual)
- Study completion
- 31 Dec 2021 (actual)
- First posted
- 22 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Eko CORE and DUO stethoscopes are FDA-approved electronic devices that have the capacity to record heart sounds. The study seeks to expand murmur detection to include VHD classification through the development of novel ML algorithms that are able to distinguish between systolic vs. diastolic vs. continuous murmurs, as well as classify VHD type and severity, using 4-point auscultation with Eko CORE and DUO electronic stethoscopes to record heart sounds.
Detailed description
Valvular heart disease (VHD), a subclass of structural heart disease (SHD), is a major cause of mortality and reduced quality of life for tens of millions of patients worldwide. Detecting VHD early allows the disease to be carefully monitored so that surgery can be considered as soon as the stenosis progresses to severe. Unfortunately, it is difficult for many clinicians to accurately identify VHD in its early stages and assess its severity through physical examination alone. This difficulty stems from both the subtlety of symptoms associated with VHD, and from clinicians' inability to reliably detect the heart murmurs indicative of VHD using a traditional stethoscope, particularly in the noisy and rushed environments characteristic of many healthcare settings.
AS, mitral regurgitation (MR), and tricuspid regurgitation (TR) all result in reliably reproducible auscultatory findings. Yet despite this, auscultation as a diagnostic procedure is notoriously poor: its accuracy to detect AS, MR, and TR ranges only from 5-40%. In addition, diastolic and continuous murmurs, which are rarer than the systolic murmurs caused by AS, MR and TR, and almost always pathologic, are usually very difficult to detect by frontline clinicians. Diastolic murmurs are typically caused by VHD such as aortic regurgitation (AR), pulmonic regurgitation (PR), mitral stenosis (MS), or tricuspid stenosis (TS), and continuous murmurs are typically caused by non-valvular forms of SHD, such as congenital aortopulmonary window, shunts, and patent ductus arteriosus (PDA). Missing one of these murmurs could lead to significantly delayed diagnosis and care.
Because of how difficult it is for clinicians to reliably screen for SHD through history taking and physical examination, the diagnosis of SHD relies heavily on echocardiography (echos), which is accepted as the gold standard for diagnosis of SHD severity by the cardiology community. The consequence of this is several-fold. First, many patients receive echos that would not be necessary if better screening and assessment tools existed. Second, echocardiography makes up a disproportionately large segment of healthcare expenditure. Third, patients are burdened with the responsibility of getting repeated echos due to the lack of better screening tools. The emotional, physical, and financial burden that accompanies such excessive testing, especially for patients living in underserved communities, cannot be overstated.
Overall, there is a growing need for better preliminary screening tools that would identify these conditions, even when asymptomatic, early on and more consistently, to a degree of accuracy comparable to gold standard echocardiography. Such a tool would improve clinicians' confidence in their assessment during physical exams, which would enable them to help their patients make informed care decisions, offer disease-altering therapies, and at the same time reduce the reliance on, and frequency of, unnecessary and expensive auxiliary workups. Lastly, by facilitating early detection of VHD, morbidity and mortality rates would be expected to decrease due to earlier intervention.
The FDA-approved Eko CORE and Eko DUO electronic stethoscopes offer clinicians a familiar and inexpensive tool that is widely accepted by patients, while at the same time offer sensors and technology that can improve screening and detection of medical conditions such as valve disease, as compared to auscultation with the traditional stethoscope. Both CORE and DUO feature sound amplification during auscultation, which improves the ability for the clinician to detect nuanced changes in heart sounds and patterns. The CORE allows recording of the audio to produce a phonocardiogram (PCG), while the DUO is able to record audio to produce a PCG as well as simultaneous recording of a single-lead electrocardiogram (ECG). Both devices use Bluetooth to wirelessly transmit PCG and ECG data to the Eko mobile application, which allows clinicians to visualize PCG and ECG as they auscultate, as well as to playback heart sound recordings, annotate notes on recorded audio, and save and share recordings. These features uniquely situate Eko electronic stethoscopes to be highly effective as preliminary screening tools in clinical practice.
Eko Devices has developed and received 510(k) FDA approval for a machine-learning (ML) algorithm that can detect the presence or absence of heart murmur in adult patients with VHD, using either the Eko CORE or DUO electronic stethoscopes to record heart sounds. This algorithm was built using a deep neural network model trained on 5,878 PCG recordings collected on Eko CORE and Eko DUO from over 5,318 unique patients to classify heart sound recordings as containing a heart murmur or containing no audible murmur, and to discriminate good quality heart sound recordings from poor quality heart sound recordings. The trained model has been independently validated in a multi-site clinical study that enrolled 681 VHD patients with matched gold-standard echocardiograms. FDA approval was received in January 2020.
The present study seeks to expand murmur detection to include VHD classification through the development of novel ML algorithms that are able to distinguish between systolic vs. diastolic vs. continuous murmurs, as well as classify VHD type and severity, using 4-point auscultation with Eko CORE and DUO electronic stethoscopes to record heart sounds. These new algorithms will integrate the time-synchronized ECG streams from DUO to improve distinction between S1 and S2 heart sounds and improve performance of identifying systolic vs. diastolic time intervals. When combined with the FDA-approved algorithm for signal quality and murmur detection, these new algorithms will enable clinicians to have a complete VHD decision support system, as based on ACC/AHA Patient Management Guidelines, when using Eko stethoscopes in their clinical practice.20 This will arm clinicians with information to help them detect SHD early, make clinical care decisions with confidence and consistency, and improve overall patient outcomes while decreasing cost and increasing efficiency.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Aortic Stenosis | – | Device: Use of Eko CORE and Eko DUO electronic stethoscopesSubjects with echo-confirmed AS graded moderate-to-severe or worse |
| Mitral Regurgitation | – | Device: Use of Eko CORE and Eko DUO electronic stethoscopesSubjects with echo-confirmed MR graded moderate-to-severe or worse |
| Tricuspid Regurgitation | – | Device: Use of Eko CORE and Eko DUO electronic stethoscopesSubjects with echo-confirmed TR graded moderate-to-severe or worse |
| Innocent Murmur | – | Device: Use of Eko CORE and Eko DUO electronic stethoscopesSubjects with echo-confirmed trace/trivial valve disease severity |
| Diastolic Murmur | – | Device: Use of Eko CORE and Eko DUO electronic stethoscopesSubjects with pathology associated with diastolic murmur (e.g. AR, PR, MS, TS) |
| Continuous Murmur | – | Device: Use of Eko CORE and Eko DUO electronic stethoscopesSubjects with pathology associated with continuous murmur (e.g. congenital shunts, PDA) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Potential research subjects will be screened for eligibility from cardiology clinics, echocardiogram clinics, and inpatient areas. Alternatively, potential subjects will be identified in the echocardiography clinic the day of their echocardiogram appointment and approached for participation once eligibility is confirmed.
Key inclusion criteria (5 listed)
- Adults aged 18 years and older
- Patient or patient's legal healthcare proxy consents to participation
- Have an audible heart murmur in at least one auscultation position, as heard by a clinician
- Undergoing or have undergone a complete (i.e., not limited) echocardiogram
- Willing to have heart recordings done with two different electronic stethoscopes
Key exclusion criteria (6 listed)
- Patient or proxy is unwilling or unable to give written informed consent
- Unable to complete a full clinical echocardiogram
- No audible heart murmur in at least one auscultation position, as heard by a clinician
- Experiencing a known or suspected acute cardiac event
- Mechanical ventricular support (such as ECMO, LVAD, RVAD, BiVAD, Impella, intra-aortic balloon pumps, TAH, VentrAssist, DuraHeart, HVAD, EVAHEART LVAS, HeartMate, Jarvik 2000)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Use of Eko CORE and Eko DUO electronic stethoscopesAuscultation of heart sounds using electronic stethoscopes | Device | Aortic Stenosis, Continuous Murmur, Diastolic Murmur, Innocent Murmur, Mitral Regurgitation, Tricuspid Regurgitation |
Primary outcome
Murmur Timing
Time frame: Within two minutes of device use
Develop a model that can classify murmurs based on the timing of the murmur in the cardiac cycle, allowing the algorithm to distinguish between systolic, diastolic, and continuous murmurs using time-synchronized ECG and PCG data.
2 secondary outcomes
Systolic Murmur Type Classification
Time frame: Within two minutes of device use
Systolic Murmur Severity Classification
Time frame: Within two minutes of device use
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2023.
Related trials for Murmur, Heart
Not yet recruiting
Exercise, Mediterranean Diet and Inflammation in Heart Failure
Heart Failure, Heart Failure Preserved Ejection Fraction
RecruitingObservational study
Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.
Atrial Fibrillation
RecruitingPhase 2
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Uncontrolled Hypertension
Recruiting
EKO SENSORA: Detecting Clinically Significant Murmurs
Heart Murmurs
Enrolling by invitationObservational study
Can Smartphones Listen to Your Heart? A Performance Study on Detecting Inborn Heart Diseases in Your Heart Sounds
Congenital Heart Disease (CHD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Murmur, Heart and Aortic Valve Stenosis, run by Eko Devices, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Murmur Timing (time frame: Within two minutes of device use). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2023.